Clinical Trial

Biomarker Discovery for Suicide Precision Circuit Therapeutics

Name: Biomarker Discovery for Suicide Precision Circuit Therapeutics — clinical trial record (NCT07723066)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting

View on ClinicalTrials.gov →

Summary

This is a prospective observational biomarker study assessing changes in clinical, behavioral, neuroimaging, and neurophysiological measurer following ketamine/esketamine or electroconvulsive therapy (ECT) in adults with suicidal thoughts or behaviors.

Trial Details

NCT Number	NCT07723066
Lead Sponsor	Massachusetts General Hospital
Conditions	Suicidal Thoughts and Behaviors, Major Depressive Episode (MDE)
Enrollment	60 participants
Start Date	2026-07
Primary Completion	2029-07 (estimated)
Study Completion	2030-08-31 (estimated)
Updated on ClinicalTrials.gov	2026-07-23